Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Scilex Holding Co's earnings before interest and taxes (EBIT) for the
three
months ended in Mar. 2026 was $-32.17 Mil.
Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was $-371.14 Mil.
EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.
Scilex Holding Co's annualizedROC % for the quarter that ended in Mar. 2026 was -33.73%.
Scilex Holding Co's annualizedROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -459.80%.
EBIT is also linked to Joel Greenblatt's definition of earnings yield.
Scilex Holding Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -256.16%.
Scilex Holding Co (NAS:SCLX) EBIT Explanation
1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.
Scilex Holding Co's annualizedROC % for the quarter that ended in Mar. 2026 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Scilex Holding Co EBIT Related Terms
Scilex Holding Co EBIT Historical Data
* Premium members only.
The historical data trend for Scilex Holding Co's EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Scilex Holding Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Scilex Holding Co EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Scilex Holding Co's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Scilex Holding Co's EV-to-EBIT falls into.
EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.
EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-371.14 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Scilex Holding Co (SCLX) has a EBIT of $-371.14 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Scilex Holding Co.
Is Scilex Holding Co's EBIT too high?
Scilex Holding Co's current EBIT is $-371.14 Mil. Overall, Scilex Holding Co has a GF Score™ of 55/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Scilex Holding Co's EBIT compare to MIRA and NSRX?
Scilex Holding Co's EBIT of $-371.14 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Scilex Holding Co. Scilex Holding Co's current EBIT is $-371.14 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scilex Holding Co stock overvalued right now?
Based on GuruFocus' analysis, Scilex Holding Co (SCLX) is currently considered Significantly Overvalued. The stock's GF Value™ is $5.90, compared to a current price of $7.95 — trading 34.7% above its estimated fair value. The current EBIT is $-371.14 Mil. Scilex Holding Co's overall GF Score™ is 55/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Scilex Holding Co (SCLX), the current EBIT is $-371.14 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Scilex Holding Co (SCLX) Overvalued in 2026?
Based on GuruFocus' analysis, Scilex Holding Co stock appears to be overvalued.
The current stock price of $7.95 is trading 34.7% above its estimated GF Value™ of $5.90.
GuruFocus considers Scilex Holding Co to be Significantly Overvalued.
Key valuation signals for SCLX:
EBIT: $-371.14 Mil
GF Value™: $5.90 vs. price of $7.95 (34.7% above fair value)
No single metric tells the full story. See the SCLX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.
55GF Score
Get the complete analysis for SCLX
EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SCLX has been successfully added to your 
